RecruitingNot ApplicableNCT07109440

The Role of the Imaging FAPI PET/CT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases

The Role of FAPI PET/CT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases: Non-randomized Phase II Molecular Imaging Study

Sponsor

Jules Bordet Institute

Enrollment

50 participants

Start Date

May 9, 2025

Study Type

INTERVENTIONAL

Conditions

Liver Metastases From Colorectal Cancer

Summary

FAPI PET/CT molecular imaging represents a cutting-edge advancement in oncological imaging, particularly for the preoperative assessment of colorectal liver metastases (CRLM). Fibroblast activation protein inhibitors (FAPIs), which are the focus of this imaging modality, selectively target cancer-associated fibroblasts, a critical component of the tumor microenvironment. FAPI PET/CT could be useful in the detection of HGP (Histological Growth Pattern) and in the changes during neoadjuvant chemotherapy prior to surgery

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using a special type of PET/CT scan with a tracer called FAPI to better understand the environment around liver metastases from colorectal cancer. The goal is to see whether this imaging can reveal features of the tumor's surroundings that might predict outcomes or guide treatment decisions. **You may be eligible if:** - You are 18 or older - You have colorectal cancer that has spread to the liver (liver metastases), confirmed on standard imaging (MRI or FDG PET/CT) - You are either treatment-naive (no prior treatment) or have received neoadjuvant chemotherapy - You are scheduled for surgical removal of the liver metastases - Your overall health is adequate (ECOG 0–2) **You may NOT be eligible if:** - Your liver metastases cannot be surgically removed - You are pregnant or breastfeeding - You have other significant medical conditions that would interfere with the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.